CME Group (NASDAQ:CME) Releases Earnings Results, Beats Expectations By $0.03 EPS

CME Group (NASDAQ:CME) posted its quarterly earnings data on Wednesday. The financial services provider reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.99 by $0.03, FiscalAI reports. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.71 billion. CME Group had a return on equity of 15.60% and a net margin of 63.30%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.68 EPS.

CME Group Price Performance

Shares of NASDAQ:CME opened at $295.31 on Wednesday. CME Group has a one year low of $218.31 and a one year high of $329.16. The stock has a fifty day moving average of $275.44 and a 200-day moving average of $270.55. The company has a market capitalization of $106.19 billion, a PE ratio of 25.05, a price-to-earnings-growth ratio of 3.79 and a beta of 0.24. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02.

CME Group Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 25th. Shareholders of record on Wednesday, September 9th were issued a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $5.20 annualized dividend and a dividend yield of 1.8%. CME Group’s dividend payout ratio is currently 44.11%.

Trending Headlines about CME Group

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record revenue and earnings beat: Third-quarter revenue reached a record $1.74 billion, above the $1.71 billion consensus estimate, while adjusted EPS of $3.02 exceeded expectations of $2.99. Net income totaled $1.04 billion and operating income was $1.14 billion. CME Group Q3 earnings release
• Positive Sentiment: Trading volumes remained strong: Average daily volume rose to a third-quarter record of 29.4 million contracts, including 9 million contracts from outside the United States. Clearing and transaction-fee revenue reached $1.4 billion, supporting double-digit revenue and net-income growth. CME Q3 record revenue report
• Positive Sentiment: Market-data growth and capital returns: Market-data revenue increased 20% to a record $243 million. CME returned nearly $1 billion to shareholders through $465 million in dividends and $524 million in share repurchases, reinforcing its cash-generation profile.
• Positive Sentiment: Product expansion offers longer-term growth opportunities: CME is pursuing tungsten futures for the first half of 2027, pending regulatory approval, and has expanded its cryptocurrency derivatives offering with Bitcoin Cash and Uniswap futures. CME tungsten futures report
• Neutral Sentiment: Institutional positioning is mixed: JPMorgan and other investors added substantial CME shares, but several large firms, including T. Rowe Price, GQG Partners, FMR and Capital Research, reduced holdings.
• Negative Sentiment: Insider selling and regulatory uncertainty remain risks: Insiders made six sales versus three purchases over the past six months, including CEO Terrence Duffy’s sale of 50,000 shares. Separately, the CFTC is asking a court to dismiss CME’s lawsuit involving crypto perpetual futures, creating uncertainty around that initiative.

Insider Transactions at CME Group

In other news, CEO Terrence A. Duffy sold 15,000 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $274.44, for a total transaction of $4,116,600.00. Following the sale, the chief executive officer directly owned 40,630 shares of the company’s stock, valued at $11,150,497.20. The trade was a 26.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Elizabeth A. Cook sold 500 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $280.11, for a total value of $140,055.00. Following the sale, the director directly owned 17,916 shares of the company’s stock, valued at approximately $5,018,450.76. This represents a 2.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on CME shares. Raymond James Financial reaffirmed an “outperform” rating and set a $320.00 target price on shares of CME Group in a research note on Thursday, July 2nd. Wells Fargo & Company lifted their target price on CME Group from $301.00 to $315.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. JPMorgan Chase & Co. boosted their price target on shares of CME Group from $249.00 to $250.00 and gave the stock an “underweight” rating in a research report on Thursday, July 23rd. Bank of America upped their price target on shares of CME Group from $226.00 to $230.00 and gave the company an “underperform” rating in a report on Thursday, July 23rd. Finally, Wall Street Zen raised shares of CME Group from a “strong sell” rating to a “sell” rating in a report on Saturday, October 3rd. Nine equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $292.94.

About CME Group

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for futures and options contracts. Its products cover major asset classes, including interest rates, equity indexes, foreign currencies, agricultural commodities, energy and metals. The company also provides market data, benchmark information and related services used by financial institutions, corporations, producers, investors and other market participants.

CME Group’s exchange portfolio includes CME, the Chicago Board of Trade, the New York Mercantile Exchange and COMEX.